Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

BACKGROUND: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may nee...

全面介紹

Na minha lista:
書目詳細資料
發表在:Exp Hematol Oncol
Main Authors: Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z., Naing, Aung, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald
格式: Artigo
語言:Inglês
出版: BioMed Central 2020
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171918/
https://ncbi.nlm.nih.gov/pubmed/32337094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00159-1
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍